Ignite Creation Date:
2024-05-06 @ 1:23 PM
Last Modification Date:
2024-10-26 @ 1:13 PM
Study NCT ID:
NCT04003636
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-05
First Post:
2019-06-28
Brief Title:
Pembrolizumab MK-3475 Plus GemcitabineCisplatin Versus Placebo Plus GemcitabineCisplatin for First-Line Advanced andor Unresectable Biliary Tract Carcinoma BTC MK-3475-966KEYNOTE-966
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC